Advanced Malignant Tumors clinical trials

Whole-body infrared hyperthermia for advanced solid tumors

This study looks at how well a treatment called whole-body infrared hyperthermia works for people with advanced solid tumors. The treatment uses heat to warm the whole body and may help fight cancer. The study will review medical records of people who already had this treatment at Zhejiang Hospital, and some people may join going forward.

Clinical Study of Three-dimensional Lattice Radiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Advanced Solid Tumors

Testing a new drug for advanced solid tumors

This trial tests an experimental drug called VBC108 in people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and effective.

Testing SW-682 in Advanced Solid Tumors

This trial tests a new drug (SW-682) for people with advanced solid tumors that have stopped responding to standard treatments. It focuses on cancers with specific gene changes (NF2 or Hippo pathway) and aims to see if the drug can shrink tumors or slow their growth.

Testing a new drug BNT326 for advanced cancers

This trial tests a new medicine called BNT326, alone or with another drug BNT327, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and might help shrink tumors.

Study of VBC101 for advanced solid tumors

This trial tests a new drug called VBC101 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if VBC101 is safe and effective.

Beta-only IL-2 therapy for advanced solid tumors

This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.

New combo for advanced solid tumors after standard therapy

This trial tests a new combination of drugs (FC084CSA plus tislelizumab) for people with advanced solid tumors, especially lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It may be an option if you've tried standard treatments and they no longer work.

Durvalumab with chemotherapy for advanced solid tumors

This trial studies durvalumab (an immune therapy) combined with chemotherapy to treat advanced solid tumors that have grown despite prior standard treatment or have no proven standard option. It aims to improve control of the cancer and help people live longer.

New drug combination for advanced solid tumors

This trial tests a new drug combination for people with advanced solid tumors. It aims to see if the combination is safe and may shrink tumors.

Study of MK-3120 for advanced solid tumors

This trial tests an investigational drug called MK-3120 for people with advanced solid tumors (cancer that has spread or cannot be removed). It is for patients whose cancer has progressed after standard treatments, and it aims to see if the drug is safe and effective.

Study drug GI-101 alone or with immune or blood-pressure meds

This early-phase study tests GI-101 in people with advanced solid cancers. It may be given alone or combined with pembrolizumab or lenvatinib to see how safe it is and whether it can shrink tumors.

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Testing a new drug for advanced solid tumors and blood cancers

This trial tests a new drug called INCA036873, which targets CD70 on cancer cells, for people with advanced solid tumors or certain blood cancers that have not responded to prior treatments. The goal is to see if it is safe and effective against these tough-to-treat cancers.

Testing TIL cell therapy for advanced solid tumors

This trial tests a type of immune cell treatment called TIL (tumor-infiltrating lymphocytes) in people with advanced solid cancers. It may help your immune system better recognize and attack tumors, especially if standard treatments have not worked.

Study of TQB6426 for advanced solid tumors

This study tests an investigational drug called TQB6426 for people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein called GPC3 found on some tumor cells. The goal is to see if the drug is safe and effective.

Belzutifan for cancers linked to VHL or HIF-2α changes

This Phase 2 study tests belzutifan (MK-6482) to treat certain advanced cancers caused by specific gene or disease changes, including VHL-related tumors and HIF-2α related tumors. It may help shrink tumors or slow their growth in people whose cancer matches these genetic or disease patterns.

Larotrectinib for tumors with extra NTRK gene copies

This trial studies larotrectinib, a targeted medicine, in people with solid tumors that have extra copies (amplification) of the NTRK1, NTRK2, or NTRK3 gene. It’s for cancers that have already been treated with standard options or where standard options are unlikely to help.

Study of ISM6331 for advanced mesothelioma or other solid tumors

This trial tests a new drug called ISM6331 for people with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The drug targets a specific pathway that may help stop tumor growth.

Avapritinib for tumors with specific KIT or PDGFRA changes

This Phase 2 trial studies avapritinib, a targeted medicine, for people whose cancer has specific KIT or PDGFRA genetic changes. It may help shrink or slow growth of certain advanced cancers, including some brain tumors, when standard treatments have not worked or for specific glioblastoma cases.

Testing three combinations for advanced solid tumors with gene defects

This Phase 1 trial tests whether adding specific medicines (talazoparib plus another drug) can help people with advanced or metastatic solid tumors that have certain gene or tumor marker changes. It also aims to find safer, workable doses and see how well these combinations work in different tumor groups.

N-3C01 Cancer Treatment Study for Advanced Solid Tumors

This trial tests a new drug called N-3C01, alone or combined with immune-boosting medications, in patients whose advanced cancer has stopped responding to standard treatments. The goal is to see if this approach can slow or shrink tumors that have become resistant to other therapies.

Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors

This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.

Testing RSC-1255 in advanced cancers with RAS changes

This early study (Phase 1) tests a new drug, RSC-1255, in people with advanced or metastatic cancers that have RAS mutations. It’s mainly focused on whether the treatment can be given safely and at what dose, and to see if it may shrink tumors.